About Ring Therapeutics
Ring Therapeutics is a Healthcare company based in Cambridge (United States) founded in 2018. It operates as a gene therapy platform developed via human commensal virome. Ring Therapeutics has raised $203.5 million across 2 funding rounds from investors including UPMC, ARE and T. Rowe Price. The company has 117 employees. Its chief executive is Tuyen Ong. Ring Therapeutics offers products and services including Anellogy Platform. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is RING THERAPEUTICS, INC. Its competitors include BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Ring Therapeutics was founded in 2018 and is headquartered in Cambridge, United States. A gene therapy platform is being developed by the company, leveraging the human commensal virome for innovative treatments. Operations center on biotechnology and gene therapy sectors, with research focused on harnessing natural viral elements. Leadership is provided by CEO Tuyen Ong, supporting advancements in therapeutic applications across the United States.
- Headquarters Cambridge, United States
- Employees 117
- SectorsHealthcare
- Website ringtx.com
- Social LinkedIn X
- Legal Name Ring Therapeutics, Inc.
- Total Equity Funding$203.5M (USD)
in 2 rounds
- Latest Funding Round$86.5M (USD), Series C
Mar 2023
- InvestorsUPMC
& 8 more
- Employee Count117
Products & Services of Ring Therapeutics
Ring Therapeutics offers a comprehensive portfolio of products and services, including Anellogy Platform.
Develops viral-based therapies using commensal virome for targeted genetic medicine applications.
Funding Insights of Ring Therapeutics
Ring Therapeutics has successfully raised a total of $203.5M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $86.5 million completed in March 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $203.5M
- Total Rounds 2
- Last Round Series C — $86.5M
- First Round $117M
(Jul 2021)
- Investors Count 9
All 2 funding rounds of Ring Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2023 | $86.5M | Series C | – | Alexandria, CJ Investment | – |
| Jul 2021 | $117M | Series B | – | – |
9 investors in total: 9 institutional.
Investors in Ring Therapeutics
Ring Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include UPMC, ARE and T. Rowe Price.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States | |
Early stage life sciences sectors focused VC firm investing in the US | – | altitudelsv.com | Kirkland, United States | |
PE firm investing in South Korea and the US | – | partnersi.co.kr | Seoul, South Korea | |
Life sciences-focused venture capital firm | 1999 | flagshippioneering.com | Cambridge, United States | |
REIT that invests in campuses, multi-tenant spaces and build-to-suit facilities in the US | 1994 | are.com | Pasadena, United States | |
Provides comprehensive investment advisory services. | 2000 | cjinvestment.net | Seoul, South Korea | |
Developer of biologics for multiple diseases and disorders | 1949 | kyowakirin.com | Chiyoda City, Japan | |
Multispecialty hospitals are operated as a nationwide chain. | 1986 | upmc.com | United States | |
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States |
Investor details for Ring Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ring Therapeutics
47 people are tracked at Ring Therapeutics (9 in leadership, 9 in board & advisors, 29 in team); the tracked headcount is 117.
| Name | Role | Group |
|---|---|---|
Tuyen Ong | CEO | Leadership |
Ashley Mackey | Senior Director, Translational Research | Leadership |
Geoffrey Parsons | Chief Scientific Officer | Leadership |
Yong S. Chang | Chief Scientific Officer | Leadership |
Christopher McNulty | CFO & Head of Corporate Strategy | Leadership |
Konstantin Konstantinov | Chief Technology Officer | Leadership |
Maciej Nogalski, PhD, MSc | Director | Leadership |
Christopher Wright | Chief Medical Officer, & Head of Translational Research | Leadership |
Timsi Rao | Associate Director | Leadership |
Don Ganem | Advisor | Board & advisors |
Hari Pujar | Director | Board & advisors |
Aravind Asokan | Advisor | Board & advisors |
Guangping Gao | Advisor | Board & advisors |
Kristian Andersen | Advisor | Board & advisors |
Avak Kahvejian | Director | Board & advisors |
Mark Kay | Advisor | Board & advisors |
Francois Nader | Director | Board & advisors |
B. Lynne Parshall | Director | Board & advisors |
Aiden(Euijoon) Jeong, PhD | Principal Scientist | Team |
Mingfang Shen | Scientist of Analytical Development, Bioprocess | Team |
27 more people are available in the full profile.
Complete people profiles for Ring Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ring Therapeutics
3 dated milestones of Ring Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Ring Therapeutics is founded.
- Funding First funding round of $117.0M.
- Funding Latest funding round, Series C, of $86.5M.
Competitors of Ring Therapeutics
Ring Therapeutics has 9 listed competitors in our database, 9 of them funded. They include BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| sentibio.com | 2016 | San Francisco, United States | $158M | – | Cell-based therapies for cancer treatment are developed. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. |
Detailed competitors of Ring Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ring Therapeutics
The website of Ring Therapeutics (ringtx.com) receives about 2.2K visits a month.
- Monthly visits2.2K
▲ 39.2% vs previous month
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Ring Therapeutics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ring Therapeutics
Complete news archive for Ring Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ring Therapeutics
Ring Therapeutics was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Ring Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Tuyen Ong is the current CEO of Ring Therapeutics.
Ring Therapeutics is a funded company, having raised a total of $203.5M across 2 funding rounds to date. The company's 1st funding round was a Series B of $117M, raised on Jul 2021.
Ring Therapeutics has 117 employees.
Ring Therapeutics was founded in 2018 and is headquartered in Cambridge, United States. A gene therapy platform is being developed by the company, leveraging the human commensal virome for innovative treatments. Operations center on biotechnology and gene therapy sectors, with research focused on harnessing natural viral elements. Leadership is provided by CEO Tuyen Ong, supporting advancements in therapeutic applications across the United States.
Ring Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Ring Therapeutics offers Anellogy Platform.
Ring Therapeutics has 9 investors. Key investors include UPMC, ARE, T. Rowe Price, Flagship Pioneering, and Kyowa Kirin.
Ring Therapeutics operates through Ring Therapeutics, Inc..